ConductScience.org, home

Paper28845751

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Ridker PM and 28 others. N Engl J Med, 2017. Cited by 7,792 papers, by iCite.

Cite this record

ConductScience Library. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. Papers, record 28845751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28845751

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
PubMed
Journal
N Engl J Med
PubMed
Year
2017
PubMed
Publication types
Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
7,792
iCite
Relative citation ratio, by iCite
306
iCite
Revised in PubMed
2026-05-18
PubMed

Authors29

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ridker PMPaul M
2Everett BMBrendan M
3Thuren TTom
4MacFadyen JGJean G
5Chang WHWilliam H
6Ballantyne CChristie
7Fonseca FFrancisco
8Nicolau JJose
9Koenig WWolfgang
10Anker SDStefan D
11Kastelein JJPJohn J P
12Cornel JHJan H
13Pais PPrem
14Pella DDaniel
15Genest JJacques
16Cifkova RRenata
17Lorenzatti AAlberto
18Forster TTamas
19Kobalava ZZhanna
20Vida-Simiti LLuminita

Source PubMed

See all 29 authorsDownload CSV of authors

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Inflammatory AgentsMajor topic
Antibodies, MonoclonalMajor topic
AtherosclerosisMajor topic
Interleukin-1betaMajor topic
Myocardial InfarctionMajor topic
Aged
Antibodies, Monoclonal, Humanized
C-Reactive Protein
Cardiovascular Diseases
Dose-Response Relationship, Drug
Double-Blind Method
Female
Humans
Incidence
Infections
Lipids
Male
Middle Aged
Neutropenia
Secondary Prevention
Stroke

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
K23 NS073806NINDS NIH HHSUnited StatesK23NS073806PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Trials12

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT01327846Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)Derived from the trialYesClinicalTrials.gov
NCT03869268The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to EndotoxinBackgroundClinicalTrials.gov
NCT04148833Treatment of Patients With Atherosclerotic Disease With Paclitaxel-associated to LDL Like NanoparticlesBackgroundClinicalTrials.gov
NCT04616872Treatment of Patients With Atherosclerotic Disease With Methotrexate-associated to LDL Like NanoparticlesBackgroundClinicalTrials.gov
NCT04735874Vascular Health and Risk Factors in Children With Down SyndromeBackgroundClinicalTrials.gov
NCT04990791WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?BackgroundClinicalTrials.gov
NCT05131750RIR and the Impact on Clinical Outcomes in Patients Undergoing PCIResultsClinicalTrials.gov
NCT05908513NAC Treatment and Outcomes in Patients With Advanced Atherosclerosis and DMBackgroundClinicalTrials.gov
NCT05956145Effect of Low Dose of Colchicine on Platelet ReactivityBackgroundClinicalTrials.gov
NCT06216847Clinical Outcomes of Patients With Coronary Artery DiseaseBackgroundClinicalTrials.gov
NCT07129850Bempedoic Acid in PPCI Impact on Clinical Outcome and Inflammatory MarkersResultsClinicalTrials.gov
NCT07331103RESOLving INflammation Through Diet for Health (RESOLVIN)BackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections13

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in28844177Targeting Inflammation in Coronary Artery Disease.https://conductscience.org/library/papers/28844177PubMed
Comment in28905870Inflammation: Targeting inflammatory pathways to treat atherosclerosis and cancer.https://conductscience.org/library/papers/28905870PubMed
Comment in29056511CANTOS Ushers in a New Calculus of Inflammasome Targeting for Vascular Protection-and Maybe More.https://conductscience.org/library/papers/29056511PubMed
Comment in29074528CANTOS Trial Validates the Inflammatory Pathogenesis of Atherosclerosis: Setting the Stage for a New Chapter in Therapeutic Targeting.https://conductscience.org/library/papers/29074528PubMed
Comment in29312693The Canakinumab Antiinflammatory Thrombosis Outcome Study trial-the starting gun has fired.https://conductscience.org/library/papers/29312693PubMed
Comment in29322754Canakinumab for Atherosclerotic Disease.https://conductscience.org/library/papers/29322754PubMed
Comment in29322755Canakinumab for Atherosclerotic Disease.https://conductscience.org/library/papers/29322755PubMed
Comment in29322756Canakinumab for Atherosclerotic Disease.https://conductscience.org/library/papers/29322756PubMed
Comment in29322757Canakinumab for Atherosclerotic Disease.https://conductscience.org/library/papers/29322757PubMed
Comment in29322758Canakinumab for Atherosclerotic Disease.https://conductscience.org/library/papers/29322758PubMed
Comment in29367331Effect size in CANTOS trial.https://conductscience.org/library/papers/29367331PubMed
Comment in29600023The quest for immunotherapy in atherosclerosis: CANTOS study, interleukin-1β and vascular inflammation.https://conductscience.org/library/papers/29600023PubMed
Comment in29607136Anti-inflammatory therapy with canakinumab for atherosclerotic disease: lessons from the CANTOS trial.https://conductscience.org/library/papers/29607136PubMed

Download CSV of comments and corrections

Cited by5,182

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7,792 citations.

PMIDTitleJournalYearIn PapersSource
42985198Biomarkers for the diagnosis and management of cardiovascular-kidney-metabolic syndrome: recent advances and prospects for clinical application.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42985198PubMed
42985003A whole-blood transcriptomic analysis of shared molecular mechanisms between subclinical atherosclerosis and hypothyroidism in women.Front Bioinform2026https://conductscience.org/library/papers/42985003PubMed
42983562Chlamydia pneumoniae orchestrates a multi-stage signaling network in atherosclerosis: from endothelial dysfunction to plaque vulnerability.Cell Commun Signal2026https://conductscience.org/library/papers/42983562PubMed
42979406Dendritic cells in atherosclerosis: integrating ontogeny, functional states, spatial organization, and therapeutic implications.Front Immunol2026https://conductscience.org/library/papers/42979406PubMed
42979111Five Trials, Five Different Questions: Design Heterogeneity Among Lipoprotein(a)-Lowering Cardiovascular Outcomes Trials After Lp(a)HORIZON.Cureus2026https://conductscience.org/library/papers/42979111PubMed
42979076NLRP3 signalling in NSCLC: distinguishing expression, inflammasome activation and context-dependent function.Front Immunol2026https://conductscience.org/library/papers/42979076PubMed
42978947Dressler syndrome and post-cardiac injury syndrome: an autoinflammatory framework for reappraising a seventy-year-old diagnosis: a state-of-the-art review.Front Immunol2026https://conductscience.org/library/papers/42978947PubMed
42977812Hematopoietic loss of KDM6A impairs cardiac recovery in heart failure via epigenetic reprogramming of myeloid cells.Nat Cardiovasc Res2026https://conductscience.org/library/papers/42977812PubMed
42974282Understanding and translating evolutionary adaptations in animals exposed to contaminated diets to guide strategies against human foodborne disease: a prioritisation framework.Front Immunol2026https://conductscience.org/library/papers/42974282PubMed
42974193Extracellular ATP Signaling as a Proposed Mechanistic Link to Cellular Senescence in Cardiovascular Diseases.J Inflamm Res2026https://conductscience.org/library/papers/42974193PubMed
42974013Strategies to reduce microvascular obstruction and infarct size in patients with ST-elevation myocardial infarction.Front Cardiovasc Med2026https://conductscience.org/library/papers/42974013PubMed
42973842Immune-driven remodeling in calcific aortic valve disease: mechanisms and immunotherapeutic opportunities.Front Immunol2026https://conductscience.org/library/papers/42973842PubMed
42973829Cross-cohort blood transcriptome analysis identifies an eight-gene diagnostic index and inflammatory programs in acute myocardial infarction.Front Cardiovasc Med2026https://conductscience.org/library/papers/42973829PubMed
42973467Association between the perivascular fat attenuation index and CCTA-defined anatomically significant left anterior descending coronary artery stenosis: relationship with serum inflammatory biomarkers.Front Cardiovasc Med2026https://conductscience.org/library/papers/42973467PubMed
42972542Pregnancy loss and prevalent cardiometabolic multimorbidity: a two-stage individual participant data analysis of CHARLS, ELSA, and HRS.BMC Womens Health2026https://conductscience.org/library/papers/42972542PubMed
42965583Cellular senescence in calcific aortic valve disease: are we ready for senolytic therapy?Mol Biol Rep2026https://conductscience.org/library/papers/42965583PubMed
42963430Cholesterol binding stabilizes the activated state of THIK-1 and promotes atherosclerosis.EMBO Rep2026https://conductscience.org/library/papers/42963430PubMed
42961237Beyond LDL-Cholesterol: Can the Neutrophil-to-HDL-Cholesterol Ratio Capture Residual Inflammatory Risk?Arq Bras Cardiol2026https://conductscience.org/library/papers/42961237PubMed
42959490Cardiovascular Risk of Conventional Synthetic, Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Common Rheumatic Diseases: A Narrative Review of Current Evidence.Ther Clin Risk Manag2026https://conductscience.org/library/papers/42959490PubMed
42959445Atherosclerosis: From Pathogenesis to Therapeutic Interventions.MedComm (2020)2026https://conductscience.org/library/papers/42959445PubMed

See all 5,182 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CRP1401PubTator's text mininghttps://conductscience.org/library/genes/1401NCBI Gene
IL1B3553PubTator's text mininghttps://conductscience.org/library/genes/3553NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
CANAKINUMABCHEMBL1201834Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1201834

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • References
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28845751

GET https://conductscience.org/api/papers/v1/28845751/authors?page=2